Oxford's OIA advances healthcare with their revolutionary platform, Algocyte
Tech.eu - 13-Sep-2023Algocyte integrates data for personalised precision medicine
The Live Forever Club is evolving. Subscribe to the newsletter to be the first to hear about this important change.
Applying Artificial General Intelligence to deliver decentralised precision health and predictive medicine
Oxford Immune Algorithmics (OIA) has transitioned its main branding and public face to Algocyte, which is the name of its flagship AI-powered remote health monitoring platform.
Algocyte® is a Physical AI-driven, end-to-end healthcare solution developed by Oxford Immune Algorithmics® (OIA), a deep-tech company incubated by Oxford University, developed in the Cambridge ecosystem and spun out from King's College London. Algocyte's ultraportable physics-informed AI medical instrument for blood testing and data-collecting platform combine subjective, contextual and objective medical data for differential diagnosis. It exploits safer and causally-grounded AI to track each individual immune system to enable precision healthcare and predictive medicine, transforming current reactive sick care to proactive real health care.
• Hector Zenil - Founder and Chief Visionary Officer
• Pamela Winsor
• Allan Bezanson
• Jesper N. Tegnér
• Michelle Lea
• Kourosh Saeb-Parsy
Visit website: https://algocyte.ai/
Details last updated 22-Aug-2026
Algocyte integrates data for personalised precision medicine
Professor of Bioscience and Computer Science at King Abdullah University of Sciences and Technology, Director at OIA
Professor of Transplantation, Laboratory & Clinical Research Group Leader at the University of Cambridge
Algocyte platform uses algorithmic inverse problem solving to aid clinicians in their diagnosis